| [1] Manzo-Merino J,Contreras-Paredes A, Vázquez-Ulloa E,et al. The role of signaling pathways in cervical cancer and molecular therapeutic targets. Arch Med Res,2014,45(7):525-539.
[2] Dasari S, Wudayagiri R, Valluru L. Cervical cancer:Biomarkers for diagnosis and treatment.Clin Chim Acta,2015,445:7-4411.
[3] Crosbie E J, Einstein M H, Franceschi S,et al. Human papillomavirus and cervical cancer. Lancet,2013,382(9895):889-899.
[4] Muñoz N, Bosch F X, de Sanjosé S,et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med,2003,348(6):518-527.
[5] Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis:roles of E6 and E7 proteins.Cancer Sci,2007,98(10):1505-1511.
[6] Miglierini P, Malhaire J P, Goasduff G,et al. Cervix cancer brachytherapy:High dose rate. Cancer Radiother, 2014,18(5-6):452-457.
[7] Pornthanakasem W, Shotelersuk K, Termrungruanglert W, et al. Human papillomavirus DNA in plasma of patients with cervical cancer. BMC Cancer, 2001,1:2.
[8] Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature, 2003, 422(6928):198-207.
[9] Bantscheff M, Kuster B. Quantitative mass spectrometry in proteomics. Anal Bioanal Chem, 2012, 404(4):937-938.
[10] 常乘,朱云平.基于质谱的定量蛋白质组学策略和方法研究进展.中国科学:生命科学,2015,45:425-438. Chang C, Zhu Y P. Strategies and algorithms for quantitative proteomics based on mass spectrometry. Scientia Sinica Vitae, 2015, 45:425-438.
[11] Srivastava S, Srivastava R G. Proteomics in the forefront of cancer biomarker discovery. J Proteome Res, 2005, 4(4):1098-1103.
[12] Marimuthu A, O'Meally R N, Chaerkady R, et al. A comprehensive map of the human urinary proteome. J Proteome Res, 2011, 10(6):2734-2743.
[13] Shao C, Wang Y, Gao Y H. Applications of urinary proteomics in biomarker discovery. Sci China Life Sci, 2011, 54:409-417.
[14] Huangda W, Sherman B T, Lempicki R A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 2009,4(1):44-57.
[15] Papachristou E K, Roumeliotis T I, Chrysagi A, et al. The shotgun proteomic study of the human thin prep cervical smear using iTRAQ mass-tagging and 2D LC-FT-Orbitrap-MS:the detection of the human papillomavirus at the protein level. J Proteome Res, 2013, 12:2078-2089.
[16] Salomon-Perzyńska M, Perzyński A, Rembielak-Stawecka B, et al. VEGF-targeted therapy for the treatment of cervical cancer-literature review. Ginekol Pol, 2014, 85(6):461-465.
[17] Gu Y, Wu S L, Meyer J L, et al. Proteomic analysis of high-grade dysplastic cervical cells obtained from ThinPrep slides using laser capture microdissection and mass spectrometry. J Proteome Res, 2007, 6(11):4256-4268.
[18] Boichenko A P, Govorukhina N, Klip H G, et al. A panel of regulated proteins in serum from patients with cervical intraepithelial neoplasia and cervical cancer. J Proteome Res, 2014,13(11):4995-5007.
[19] Guo X, Hao Y, Kamilijiang M, et al. Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and Ingenuity Pathway Analysis. Tumour Biol, 2015,36(3):1711-1720.
[20] Aobchey P, Niamsup H, Siriaree S, et al. Proteomic analysis of candidate prognostic uinary marker for cervical cancer. J Proteomics, 2013,6(11):245-251.
[21] Van Raemdonck G A, Tjalma W A, Coen E P, et al. Identification of protein biomarkers for cervical cancer using human cervicovaginal fluid. PLoS One, 2014,9(9):e106488.
[22] Tindle R W. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer, 2002,2(1):59-65.
[23] Multhaupt H A, Leitinger B, Gullberg D, et al. Extracellular matrix component signaling in cancer. Adv Drug Deliv, 2016,97:28-40.
[24] Hanahan D, Weinberg R A. Hallmarks of cancer:the next generation. Cell, 2011,144(5):646-674.
[25] Lam C S, Cheung A H, Wong S K, et al. Prognostic significance of CD26 in patients with colorectal cancer. PLoS One, 2014,9(5):e98582.
[26] Inamoto T, Yamada T, Ohnuma K, et al. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res, 2007,13(14):4191-4200.
[27] Pang R, Law W L, Chu A C, et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell, 2010,6(6):603-615.
[28] Ghani F I, Yamazaki H, Iwata S, et al. Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem Biophys Res Commun, 2011,404(2):735-742.
[29] Havre P A, Abe M, Urasaki Y, et al. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci, 2008,13:1634-1645.
[30] Bauvois B. A collagen-binding glycoprotein on the surface of mouse fibroblasts is identified as dipeptidyl peptidase IV. Biochem J, 1988,252(3):723-731.
[31] Gonzalez-Gronow M, Kaczowka S, Gawdi G, et al. Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor. Front Biosci, 2008,13:1610-1618.
[32] Sedo A, Stremenová J, Bušek P, et al. Peptidyl peptidase-IV and related molecules:markers of malignancy. Expert Opin Med Diagn, 2008,2(6):677-689.
[33] Kacar A, Arikok A T, Kokenek Unal T D, et al. Stromal expression of CD34, α-smooth muscle actin and CD26/DPPIV in squamous cell carcinoma of the skin:a comparative immunohistochemical study. Pathol Oncol Res, 2012,18(1):25-31.
[34] Watson P H. Psoriasin (S100A7). The International Journal of Biochemistry & Cell Biology, 1998,30:567-571.
[35] Schäfer B W, Heizmann C W. The S100 family of EFhand calcium binding proteins:functions and pathology. Trends Biochem Sci, 1996,21(4):134-140.
[36] Donato R. S100:a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol, 2001,33(7):637-668.
[37] Zimmer D B, Cornwall E H, Landar A, et al. The S100 protein family:history, function, and expression. Brain Res Bull, 1995,37(4):417-429.
[38] Algermissen B, Sitzmann J, LeMotte P, et al. Differential expression of CRABP Ⅱ, psoriasin and cytokeratin 1 mRNA in human skin diseases. Arch Dermatol Res, 1996,288(8):426-430.
[39] Al-Haddad S, Zhang Z, Leygue E,et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol, 1999, 155(6):2057-2066.
[40] Enerbäck C, Porter D A, Seth P, et al. Psoriasin expression in mammary epithelial cells in vitro and in vivo. Cancer Res, 2002,62(1):43-47.
[41] Moubayed N, Weichenthal M, Harder J, et al. Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumors. J Cancer Res Clin Oncol, 2007,133(4):253-261.
[42] Ostergaard M, Rasmussen H H, Nielsen H V, et al. Proteome profiling of bladder squamous cell carcinomas:identification of markers that define their degree of differentiation. Cancer Res, 1997,57(18):4111-4117.
[43] Moog-Lutz C, Bouillet P, Régnier C H, et al. Comparative expression of the psoriasin (S100A7) and S100C genes in breast carcinoma and co-localization to human chromosome 1q21-q22. Int J Cancer, 1995,63(2):297-303.
[44] Leygue E, Snell L, Hiller T, et al. Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma. Cancer Res, 1996,56(20):4606-4609.
[45] Dey K K, Sarkar S, Pal I, et al. Mechanistic attributes of S100A7(psoriasin) in resistance of anoikis resulting tumor progression in squamous cell carcinoma of the oral cavity. Cancer Cell Int, 2015,15:94.
[46] Krop I, März A, Carlsson H A, et al. Putative role for psoriasin in breast tumor progression. Cancer Res, 2005,65(24):11326-11334.
[47] Royse K E, Zhi D, Conner M G, et al. Differential gene expression landscape of co-existing cervical pre-cancer lesions using RNA-seq. Front Oncol, 2014,4:339.
[48] Hammarström S. The carcinoembryonic antigen (CEA) family:structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol, 1999,9(2):67-81.
[49] Yoon J, Terada A, Kita H. CD66b regulates adhesion and activation of human eosinophils. J Immunol, 2007,179(12):8454-8462.
[50] Skubitz KM, Skubitz AP. Interdependency of CEACAM-1, -3, -6, and -8 induced human neutrophil adhesion to endothelial cells. J Transl Med, 2008, 6(1):78.
[51] Torsteinsdóttir I, Arvidson N G, Hällgren R, et al. Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils in patients with rheumatoid arthritis, and the effect of glucocorticoids. Scand J Immunol, 1999,50(4):433-439.
[52] Zhao L, Xu S, Fjaertoft G, et al. An enzyme-linked immunosorbent assay for human carcinoembryonic antigen-related cell adhesion molecule 8, a biological marker of granulocyte activities in vivo. J Immunol Methods, 2004,293(1-2):207-214.
[53] Mawhorter S D, Stephany D A, Ottesen E A, et al. Identification of surface molecules associated with physiologic activation of eosinophils:application of whole-blood flow cytometry to eosinophils. J Immunol, 1996,156(12):4851-4858.
[54] Schmidt T, Zündorf J, Grüger T, et al. CD66b overexpression and homotypic aggregation of human peripheral blood neutrophils after activation by a gram-positive stimulus. J Leukoc Biol, 2012,91(5):791-802.
[55] Graham R A, Wang S, Catalano P J, et al. Postsurgical surveillance of colon cancer:preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg, 1998,228(1):59-63.
[56] Grunnet M, Sorensen J B. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer, 2012,76(2):138-143.
[57] Esteban J M, Felder B, Ahn C, et al. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer, 1994,74(5):1575-1583.
[58] Kim J, Kaye F J, Henslee J G, et al. Expression of carcinoembryonic antigen and related genes in lung and gastrointestinal cancers. Int J Cancer, 1992,52(5):718-725. |
